Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | GGH | Q92820 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29105485 | 0.84 | MEN1 (0.37) | MEN1GAAKMT2A | |
| SCHEMBL6921214 | 0.80 | CTSL (0.43) | FOLH1MEN1GAAKMT2A | |
| SCHEMBL4416791 | 0.80 | CTSL (0.43) | FOLH1MEN1GAAKMT2A | |
| SCHEMBL1564466 | 0.79 | FOLH1 (0.40) | FOLH1NAALAD2RIMKLAGGHMEN1 | |
| SCHEMBL29274486 | 0.79 | MEN1 (0.36) | MEN1GAAKMT2A | |
| SCHEMBL1248320 | 0.78 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL9696087 | 0.78 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL5575587 | 0.78 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL626934 | 0.78 | FOLH1 (0.44) | FOLH1NAALAD2RIMKLAGGHMEN1 | |
| SCHEMBL626933 | 0.78 | FOLH1 (0.44) | FOLH1NAALAD2RIMKLAGGHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6472541-B2 | HALOGENATED- COUMARIN, QUINOLINE-2-ONE, XANTHENE, THIOXANTHENE, SELENOXANTHENEN, OR ANTHRACENE DERIVATIVES; IRRADIATING TO CONTROL THE RELEASE OF THE SOMPOUND SPATIALLY AND TEMPORALLY TO PROBE ITS BIOLOGICAL EFFECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-10-29 | — | — | US | disclosed |
| EP-1151350-A4 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | UNIV CALIFORNIA (US) | 2002-08-21 | — | — | EP | disclosed |
| US-20020016472-A1 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-02-07 | — | — | US | disclosed |
| EP-1151350-A1 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | The Regents of the University of California (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000031588-A1 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016472-A1 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | ERCC4, XPA, GPX4 | FOLH1 2487/4885NAALAD2 2551/4885RIMKLA 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.